Warren Center for Neuroscience Drug Discovery
Turning Heads: The Vanderbilt Brain Institute has emerged as a hub of discovery as neuroscience’s influence expands
Aug. 5, 2020—The VBI recently marked its 20th anniversary, a span that has seen the institute’s wide-ranging missions—including administering the university’s Neuroscience Graduate Program, as well as postdoctoral training and community outreach—steadily coalesce under a single umbrella.
Jul. 23, 2020—VU319, an investigational drug product developed by Vanderbilt researchers, targets one of medicine’s most bedeviling challenges: improving memory loss in people with Alzheimer’s disease.
Vanderbilt University partners with ACADIA Pharmaceuticals to develop novel treatments for central nervous system disorders
Jun. 16, 2020—Vanderbilt University’s Warren Center for Neuroscience Drug Discovery has entered into an exclusive worldwide licensing and collaboration agreement with San Diego-based ACADIA Pharmaceuticals Inc. to develop treatments for disorders like Alzheimer’s and schizophrenia.
Leader in Vanderbilt drug discovery efforts, Craig Lindsley named interim editor-in-chief of ACS Pharmacology & Translational Science
Jun. 12, 2020—Craig Lindsley, William K. Warren, Jr. Chair in Medicine and university professor of biochemistry, chemistry and pharmacology, has been named interim editor-in-chief of the journal "ACS Pharmacology & Translational Science."
Vanderbilt receives $20 million from The William K. Warren Foundation to further treatments for brain disorders
May. 5, 2020—Vanderbilt University has received $20 million from The William K. Warren Foundation, located in Tulsa, Oklahoma, to establish the Warren Center for Neuroscience Drug Discovery to support pharmaceutical breakthroughs.